Bolt Biotherapeutics
Justin Kenkel is a seasoned scientist with extensive experience in biotherapeutics and immunology. Currently serving as Principal Scientist at Bolt Biotherapeutics, Inc. since August 2018, Justin has held progressive roles including Senior Scientist and Scientist II. Prior to this, a postdoctoral fellow in Pathology at Stanford University School of Medicine from January 2015 to July 2018 and a Graduate Student Researcher in Immunology there from 2007 to 2014 further honed Justin's expertise. Earlier roles include Research Scientist in Rheumatology at the University of Washington and Pharmacopathology Intern at Berlex Biosciences. Justin holds a Ph.D. in Immunology from Stanford University and a Bachelor's degree in Molecular and Cell Biology from the University of California, Berkeley.
This person is not in any teams
Bolt Biotherapeutics
7 followers
Bolt Biotherapeutics, Inc., based in the San Francisco Bay Area, is a publicly-traded biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients.